Abstract
In diabetic disease, blood glucose, HbA1c and insulin levels qualify as biomarkers reflecting endocrine pancreas function, but their shortfall in being truly useful predictors or surrogate endpoints of “abnormal processes or disease“ lies in that alteration in their levels are dependent on a variety comorbidities and occur too late in the disease process to be useful sentinels. Non invasive imaging of molecular targets within the beta cell carry the promise of revealing quantitative information about β-cell mass that can, at least theoretically, be used to monitor, in real-time, the natural history of T1DM progression, assess novel therapies designed to drive the proliferation and differentiation of endogenous beta cell progenitors, appraise methods of preserving mature beta cell mass as well as to track the function and viability of transplanted cells and tissues. In this article, we review and deconstruct available information regarding the methodology of making non invasive measurements of VMAT2 in the pancreas and the validity of these measurements to estimate beta cell mass in vivo.
Keywords: VMAT2, PET, diabetes, beta cell mass, DTBZ
Current Pharmaceutical Design
Title: In Vivo Beta-Cell Imaging with VMAT 2 Ligands - Current State-of-the-Art and Future Perspectives
Volume: 16 Issue: 14
Author(s): Rajakrishnan Veluthakal and Paul Harris
Affiliation:
Keywords: VMAT2, PET, diabetes, beta cell mass, DTBZ
Abstract: In diabetic disease, blood glucose, HbA1c and insulin levels qualify as biomarkers reflecting endocrine pancreas function, but their shortfall in being truly useful predictors or surrogate endpoints of “abnormal processes or disease“ lies in that alteration in their levels are dependent on a variety comorbidities and occur too late in the disease process to be useful sentinels. Non invasive imaging of molecular targets within the beta cell carry the promise of revealing quantitative information about β-cell mass that can, at least theoretically, be used to monitor, in real-time, the natural history of T1DM progression, assess novel therapies designed to drive the proliferation and differentiation of endogenous beta cell progenitors, appraise methods of preserving mature beta cell mass as well as to track the function and viability of transplanted cells and tissues. In this article, we review and deconstruct available information regarding the methodology of making non invasive measurements of VMAT2 in the pancreas and the validity of these measurements to estimate beta cell mass in vivo.
Export Options
About this article
Cite this article as:
Veluthakal Rajakrishnan and Harris Paul, In Vivo Beta-Cell Imaging with VMAT 2 Ligands - Current State-of-the-Art and Future Perspectives, Current Pharmaceutical Design 2010; 16 (14) . https://dx.doi.org/10.2174/138161210791164180
DOI https://dx.doi.org/10.2174/138161210791164180 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenetics Strategies: From Candidate Genes to Whole-Genome Association Analysis. Exploratory or Confirmatory Studies?
Current Pharmacogenomics and Personalized Medicine Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease
Current Vascular Pharmacology Pleiotropic Effects of Statin in Therapy in Heart Failure: A Review
Current Vascular Pharmacology Headache, Outpatient Management and Referral to Specialty Clinics, Clinical Audit
New Emirates Medical Journal Cellular and Molecular Mechanisms of Dementia: Decoding the Causal link of Diabetes Mellitus in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets A New Alzheimers Disease Interventive Strategy: GLP-1
Current Drug Targets Alzheimer Biomarkers and Clinical Alzheimer Disease were Not Associated with Increased Cerebrovascular Disease in a Memory Clinic Population
Current Alzheimer Research Humanin: A Possible Linkage Between Alzheimer’s Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets Atrial Fibrillation in Heart Failure: An Innocent Bystander?
Current Cardiology Reviews Molecular Characterization of the Hetero-Assembly of β-Amyloid Peptide with Islet Amyloid Polypeptide
Current Pharmaceutical Design Recent Advances in Drug Delivery Systems for Anti-Diabetic Drugs: A Review
Current Drug Delivery Emerging Therapy for Diabetic Neuropathy: Cell Therapy Targeting Vessels and Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Cholesterol, Lipids, Amyloid Beta, and Alzheimers
Current Alzheimer Research Metabolic Features of Alcoholic Liver Disease
Reviews on Recent Clinical Trials Development and Characterization of Cassia grandis and Bixa orellana Nanoformulations
Current Topics in Medicinal Chemistry Cognitive Function and the Ageing Process: The Peculiar Role of Mild Thyroid Failure
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness
Current Diabetes Reviews Pharmacotherapy of Aortic Stenosis-Success or Failure?
Current Pharmaceutical Biotechnology Soy Isoflavones and Cardiovascular Disease Epidemiological, Clinical and -Omics Perspectives
Current Pharmaceutical Biotechnology Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets